{"page":{"totalFilteredElements":344},"studies":[{"active":true,"description":"Wirksamkeit und Sicherheit von Carfilzomib in Kombination mit Ibrutinib oder Ibrutinib alleine bei Patienten mit Morbus Waldenström (CZAR-1)","eudractNumber":"2018-003526-88","id":7449,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD20","id":"mt_77"},{"name":"CXCR4 (C-X-C chemokine receptor type 4)","id":"mt_177"}],"nctNumber":"NCT04263480","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-04-28T11:27:47+02:00","shortTitle":"CZAR-1","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"
Clinical Research Platform On Renal Cell Carcinoma Treatment And Outcome (Registry Platform Renal Cell Carcinoma; CARAT)

","eudractNumber":null,"id":8281,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"}],"mutations":[],"nctNumber":"NCT03374267","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-03-01T13:38:19+01:00","shortTitle":"Carat","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Clinical Research Platform On Renal Cell Carcinoma Treatment And Outcome (Registry Platform Renal Cell Carcinoma; CARAT)","eudractNumber":null,"id":4795,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"}],"mutations":[],"nctNumber":"NCT03374267 ","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2017-11-30T09:34:51+01:00","shortTitle":"Carat","therapeutical":false,"therapyLines":[]},{"active":true,"description":"

A phase 2b, randomized, blinded,\nplacebo-controlled trial investigating the efficacy and safety of visugromab\nversus placebo, both in combination with pembrolizumab, pemetrexed, and\ncis-/carboplatin, in participants with newly diagnosed metastatic non-squamous\nnon-small cell lung cancer (GDFATHER-LUNG-01)

","eudractNumber":"2024-516792-32","id":10166,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[],"nctNumber":"NCT07098988","phase":{"id":"ph_16","name":"IIB"},"recruitmentStart":"2026-01-14T12:47:14+01:00","shortTitle":"Catalym CTL-002-003 GDFATHER-LUNG-01","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A phase 2b, randomized, blinded, placebo-controlled trial investigating the efficacy of visugromab plus nivolumab in combination with docetaxel versus docetaxel alone in metastatic non-squamous non-small-cell lung cancer (nsq-NSCLC) after failing one prior line of systemic treatment containing a checkpoint inhibitor for advanced/metastatic nsq-NSCLC","eudractNumber":"2024-516794-70","id":10165,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[],"nctNumber":"NCT07246863","phase":{"id":"ph_16","name":"IIB"},"recruitmentStart":"2026-02-24T15:23:34+01:00","shortTitle":"Catalym CTL-002-004 GDFATHER-LUNG-02","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Charakterisierung\ndes Signalnetzwerkes und der Mikroumgebung in Plasmazelldyskrasien","eudractNumber":null,"id":11386,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2025-02-01T11:16:33+01:00","shortTitle":"Charakterisierung des Signalnetzwerkes und der Mikroumgebung in Plasmazelldyskrasien","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Charakterisierung des onkogenen \nSignalnetzwerkes im Multiplen Myelom: Entwicklung neuer zielgerichteter \nTherapieansätze (Folgeprojekt)","eudractNumber":null,"id":2252,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2013-04-21T11:13:57+02:00","shortTitle":"Charakterisierung des onkogenen Signalnetzwerkes im Multiplen Myelom: Entwicklung neuer zielgerichteter Therapieansätze (Folgeprojekt)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Evaluierung der adjuvanten Therapie beim Dickdarmkrebs im Stadium II nach ctDNA-Bestimmung","eudractNumber":"2018-003691-12","id":5573,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[{"name":"Mismatch Repair Deficiency (dMMR)","id":"mt_270"},{"name":"MSI (Mikrosatelitteninstabilität)","id":"mt_51"},{"name":"MSI-H","id":"mt_52"}],"nctNumber":"NCT04089631","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2020-08-07T08:25:33+02:00","shortTitle":"Circulate AIO-KRK-0217","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"
COLOPREDICT PLUS 2.0 Register
Retro- und prospektive Erfassung der Rolle von MSI und KRAS für die Prognose beim Kolonkarzinom im Stadium I + II + III

DRKS00004305 (keine weiteren Registriernummern)
","eudractNumber":null,"id":3456,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2016-11-15T08:26:00+01:00","shortTitle":"ColoPredict Plus 2.0 Register","therapeutical":false,"therapyLines":[]},{"active":true,"description":"
COLOPREDICT PLUS 2.0 Register
Retro- und prospektive Erfassung der Rolle von MSI und KRAS für die Prognose beim Kolonkarzinom im Stadium I + II + III

DRKS00004305 (keine weiteren Registriernummern)
","eudractNumber":null,"id":4652,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2021-06-19T14:47:34+02:00","shortTitle":"ColoPredict Plus 2.0 Register","therapeutical":false,"therapyLines":[]}]}